Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases

Title:Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases

Volume: 23 Issue: 21

Author(s): Segura-Uribe Julia J, Ciprés-Flores Fabiola Jimena, Farfán-García Eunice Dalet, Trujillo-Ferrara José Guadalupe and Soriano-Ursúa Marvin Antonio*

Affiliation:

• Departamento de Fisiología, Escuela Superior de Medicina, Instituto Politécnico Nacional. Plan de San Luis y Díaz Mirón, C.P. 11340, Ciudad de México,Mexico

Keywords: Central nervous system, neurodegenerative disease, nanoparticles, nanoliposomes, drug delivery, Parkinson's disease.

Abstract: Background: Lipid nanoparticles have been studied mainly as a means of transporting and releasing drugs. A special emphasis has been placed on designing nanoparticles that improve the delivery of drugs with targets in the central nervous system.

Methods: The biomedical literature was searched for basic and clinical studies. The recent applications are described and related with their bioactivities.

Results: The current review compiles data on the components and features of lipid nanoparticle systems as well as the necessary conditions for their selective action. As an example of their application, we present data from preclinical and clinical studies on lipid nanoparticles used as potent and efficient agents in the diagnosis and treatment of some neurodegenerative maladies, including Parkinson’s disease.

Conclusion: Current evidence supports the application of lipid nanoparticles for designing drugs carriers for neurodegenerative diseases. Also, we have gathered data that suggests a role of drug-free lipid nanoparticles as neuroprotective or preventive agents during neurodegenerative processes.

Cite this article as:

J Julia Segura-Uribe, Jimena Fabiola Ciprés-Flores, Dalet Eunice Farfán-García, Guadalupe José Trujillo-Ferrara and Antonio Marvin Soriano-Ursúa*, Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases, Current Pharmaceutical Design 2017; 23 (21) . https://dx.doi.org/10.2174/1381612823666170301123504

DOI https://dx.doi.org/10.2174/1381612823666170301123504	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286